Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/26/2026 | Q4 | $3.3M | -- | -- | -$1.36 | -- |
| 11/06/2025 | Q3 | $394K | $143K | -$1.38 | -$1.25 | -$0.13 |
| 08/07/2025 | Q2 | $485.8K | $1M | -$1.23 | -$1.10 | -$0.13 |
| 05/08/2025 | Q1 | $100K | $361K | -$1.04 | -$0.95 | -$0.09 |
| 02/27/2025 | Q4 | $727.3K | -- | -$0.88 | -$0.89 | $0.01 |
| 11/12/2024 | Q3 | $239.9K | -- | -$0.96 | -$0.91 | -$0.05 |
| 08/08/2024 | Q2 | $467.3K | -- | -$0.94 | -$0.86 | -$0.07 |
| 05/09/2024 | Q1 | $181.8K | -- | -$0.93 | -$0.81 | -$0.12 |
| 02/28/2024 | Q4 | $182.9K | -- | -$0.90 | -$0.87 | -$0.02 |
| 11/07/2023 | Q3 | $141.1K | -- | -$1.01 | -$0.88 | -$0.13 |
| 08/08/2023 | Q2 | -- | -- | -$0.94 | -- | -- |
| 05/04/2023 | Q1 | -- | -- | -$0.85 | -- | -- |
| 02/28/2023 | Q4 | -- | $709K | -$0.84 | -- | -- |
| 11/14/2022 | Q3 | -- | -- | -$0.78 | -- | -- |
| 08/12/2022 | Q2 | -- | -- | -$0.81 | -- | -- |
| 05/12/2022 | Q1 | -- | -- | -$0.73 | -- | -- |
| 03/30/2022 | Q4 | -- | $1.1M | -$0.68 | -- | -- |
| 11/05/2021 | Q3 | -- | -- | -$0.73 | -- | -- |
| 08/10/2021 | Q2 | -- | -- | -$0.70 | -- | -- |
| 05/06/2021 | Q1 | -- | -- | -$0.69 | -- | -- |
| 03/30/2021 | Q4 | -- | -- | -$0.66 | -- | -- |
| 11/06/2020 | Q3 | -- | -- | -$0.56 | -- | -- |
| 08/07/2020 | Q2 | -- | -- | -$0.53 | -- | -- |
| 05/08/2020 | Q1 | -- | -- | -$0.71 | -- | -- |
| 03/09/2020 | Q4 | -- | -- | -$0.60 | -- | -- |
| 11/12/2019 | Q3 | -- | -- | -$0.60 | -- | -- |
| 08/13/2019 | Q2 | -- | -- | -$0.51 | -- | -- |
| 05/13/2019 | Q1 | -- | -- | -$0.37 | -- | -- |
| 02/13/2019 | Q4 | -- | -- | -$0.35 | -- | -- |
| 11/13/2018 | Q3 | -- | -- | -$0.38 | -- | -- |
| 08/30/2018 | Q2 | -- | -- | -$0.73 | -- | -- |
| 03/31/2018 | Q1 | -- | -- | -$0.23 | -- | -- |
| 12/31/2017 | Q4 | -- | -- | -$0.18 | -- | -- |
| 09/30/2017 | Q3 | -- | -- | -$0.10 | -- | -- |
| 06/30/2017 | Q2 | -- | -- | -$0.12 | -- | -- |
| 03/31/2017 | Q1 | -- | -- | -$0.11 | -- | -- |
Crinetics Pharmaceuticals, Inc. reported $143K worth of top line sales in its most recent quarter.
Crinetics Pharmaceuticals, Inc. announced earnings per share of -$1.38 which represents a miss of analyst forecast a -$1.25 per share.
Crinetics Pharmaceuticals, Inc. reported -$869K that represents -$0.01 per share over the last quarter.
Crinetics Pharmaceuticals, Inc.'s earnings are forecast to decrease from -$3.69 per share to -$3.71 per share next year representing a decrease of -34.06%.
Crinetics Pharmaceuticals, Inc.'s next earnings date is February 26, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.